免疫疗法和三阴性乳腺癌的联合治疗:一个Scopus图书统计视角
Ninie Nadia Zulkipli1,2, Imilia Ismail2, Wan Rohani Wan Taib2
1Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
Future oncology (London, England)
|July 21, 2025
概括
这项研究分析了1818篇关于2019-2023年三阴性乳腺癌 (TNBC) 免疫治疗的出版物. 关键的研究领域包括免疫检查点抑制剂 (ICI),PD-L1和瘤微环境 (TME),以更好地管理TNBC.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 图书统计学 图书统计学
背景情况:
- 免疫疗法对三阴性乳腺癌 (TNBC) 至关重要,但作为单一疗法具有局限性.
- 全球研究重点是TNBC有效的组合免疫疗法.
- 确定新的治疗策略对于改善患者的治疗结果至关重要.
研究的目的:
- 提供过去五年TNBC免疫疗法研究的概述.
- 确定TNBC免疫疗法的新兴研究热点和趋势.
- 为了为TNBC管理的未来研究方向提供信息.
主要方法:
- 从Scopus (2019-2023) 中对1,818篇出版物的图书统计分析.
- 使用哈尔辛的发布或死亡,微软Excel和VOSviewer进行数据分析.
- 检查了出版趋势,国家合作和关键词的共同出现.
主要成果:
- 关于TNBC免疫治疗的出版物产量稳步增加.
- 亚洲和美国是领先的研究贡献者,有着强大的美中合作.
- 免疫检查点抑制剂 (ICI),PD-L1和瘤微环境 (TME) 被确定为关键研究热点.
结论:
- 组合免疫疗法方法对于推进TNBC治疗至关重要.
- 对ICI,PD-L1和TME等已识别的热点进行进一步的研究可以提供新的治疗途径.
- 整合这些热点的知识可能会导致改善TNBC管理策略.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


